• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Evaluation of five carbapenemase detection assays for Enterobacteriaceae harbouring blaKPC variants associated with ceftazidime/avibactam resistance.

作者信息

Gaibani Paolo, Lombardo Donatella, Foschi Claudio, Re Maria Carla, Ambretti Simone

机构信息

Operative Unit of Clinical Microbiology, S. Orsola-Malpighi University Hospital, Bologna, Italy.

DIMES, University of Bologna, Bologna, Italy.

出版信息

J Antimicrob Chemother. 2020 Jul 1;75(7):2010-2013. doi: 10.1093/jac/dkaa079.

DOI:10.1093/jac/dkaa079
PMID:32182346
Abstract
摘要

相似文献

1
Evaluation of five carbapenemase detection assays for Enterobacteriaceae harbouring blaKPC variants associated with ceftazidime/avibactam resistance.对携带与头孢他啶/阿维巴坦耐药相关的blaKPC变体的肠杆菌科细菌进行五种碳青霉烯酶检测方法的评估。
J Antimicrob Chemother. 2020 Jul 1;75(7):2010-2013. doi: 10.1093/jac/dkaa079.
2
Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.头孢他啶-阿维巴坦对一组碳青霉烯类耐药肠杆菌科挑战株的活性：OmpK36 L3 改变和具有头孢他啶水解活性的β-内酰胺酶导致 MIC 值升高。
Int J Antimicrob Agents. 2020 Jul;56(1):106011. doi: 10.1016/j.ijantimicag.2020.106011. Epub 2020 May 15.
3
Low Frequency of Ceftazidime-Avibactam Resistance among Enterobacteriaceae Isolates Carrying Collected in U.S. Hospitals from 2012 to 2015.2012年至2015年在美国医院收集的携带[相关因素未给出]的肠杆菌科分离株中头孢他啶-阿维巴坦耐药的低发生率
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02369-16. Print 2017 Mar.
4
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.耐碳青霉烯类肺炎克雷伯菌感染治疗期间因质粒介导的突变导致头孢他啶-阿维巴坦耐药的出现
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02097-16. Print 2017 Mar.
5
Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16.2015-2016 年英国分离的产 ESBL 肠杆菌科细菌和铜绿假单胞菌对头孢他啶/阿维巴坦的活性。
J Antimicrob Chemother. 2018 Mar 1;73(3):648-657. doi: 10.1093/jac/dkx438.
6
In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase.携带KPC-3碳青霉烯酶的肠杆菌科细菌对头孢他啶-阿维巴坦耐药性的体外筛选
Antimicrob Agents Chemother. 2015 Sep;59(9):5324-30. doi: 10.1128/AAC.00678-15. Epub 2015 Jun 22.
7
Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in -Harboring Klebsiella pneumoniae Sequence Type 307 Isolates.携带blaKPC-2 的肺炎克雷伯菌序列型 307 分离株通过不同的基因组适应性连续出现头孢他啶-阿维巴坦耐药性。
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.02101-17. Print 2018 Mar.
8
Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.在法国一项前瞻性区域间调查中收集的碳青霉烯不敏感肠杆菌分离株的分子特征以及对新型头孢他啶-阿维巴坦和氨曲南-阿维巴坦联合制剂的敏感性
Antimicrob Agents Chemother. 2015 Oct 19;60(1):215-21. doi: 10.1128/AAC.01559-15. Print 2016 Jan.
9
In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017).亚太地区 INFORM 项目（2015-2017 年）收集的革兰氏阴性细菌分离株的头孢他啶-阿维巴坦和对照药物的体外活性。
Ann Clin Microbiol Antimicrob. 2020 Apr 1;19(1):14. doi: 10.1186/s12941-020-00355-1.
10
Mutations in That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-Lactamases.赋予头孢他啶-阿维巴坦耐药性的突变编码新型KPC-3变体，其作为超广谱β-内酰胺酶发挥作用。
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.02534-16. Print 2017 May.

引用本文的文献

1
Newly developed antibiotics against multidrug-resistant and carbapenem-resistant Gram-negative bacteria: action and resistance mechanisms.针对多重耐药和碳青霉烯耐药革兰氏阴性菌的新型抗生素：作用机制与耐药机制
Arch Microbiol. 2025 Apr 2;207(5):110. doi: 10.1007/s00203-025-04298-z.
2
Antimicrobial and Diagnostic Stewardship of the Novel β-Lactam/β-Lactamase Inhibitors for Infections Due to Carbapenem-Resistant Enterobacterales Species and .新型β-内酰胺/β-内酰胺酶抑制剂对耐碳青霉烯类肠杆菌科细菌感染的抗菌及诊断管理
Antibiotics (Basel). 2024 Mar 21;13(3):285. doi: 10.3390/antibiotics13030285.
3
Rapid Detection of Ceftazidime/Avibactam Susceptibility/Resistance in Enterobacterales by Rapid CAZ/AVI NP Test.
快速 CAZ/AVI NP 试验检测肠杆菌科中头孢他啶/阿维巴坦的药敏/耐药性。
Emerg Infect Dis. 2024 Feb;30(2):255-261. doi: 10.3201/eid3002.221398.
4
Prevalence and mortality of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae bloodstream infections (2018-2022).产头孢他啶/阿维巴坦耐药 KPC 肺炎克雷伯菌血流感染的流行率和死亡率（2018-2022 年）。
Eur J Clin Microbiol Infect Dis. 2024 Jan;43(1):155-166. doi: 10.1007/s10096-023-04712-8. Epub 2023 Nov 21.
5
Rapid diagnostics and ceftazidime/avibactam for KPC-producing Klebsiella pneumoniae bloodstream infections: impact on mortality and role of combination therapy.产碳青霉烯酶肺炎克雷伯菌血流感染的快速诊断与头孢他啶/阿维巴坦：对死亡率的影响及联合治疗的作用。
Eur J Clin Microbiol Infect Dis. 2023 Apr;42(4):431-439. doi: 10.1007/s10096-023-04577-x. Epub 2023 Feb 20.
6
Implementation of Chromatic Super CAZ/AVI medium for active surveillance of ceftazidime-avibactam resistance: preventing the loop from becoming a spiral.实施色氨酸 CAZ/AVI 培养基主动监测头孢他啶-阿维巴坦耐药性：防止循环变成螺旋。
Eur J Clin Microbiol Infect Dis. 2022 Sep;41(9):1165-1171. doi: 10.1007/s10096-022-04480-x. Epub 2022 Aug 6.
7
Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing.革兰氏阴性多重耐药杆菌对头孢他啶/阿维巴坦、美罗培南/瓦博巴坦和亚胺培南/瑞来巴坦的耐药性：分子机制与药敏试验
Antibiotics (Basel). 2022 May 6;11(5):628. doi: 10.3390/antibiotics11050628.
8
Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 -Producing KPC-31, a D179Y Variant of KPC-3.美罗培南-巴硼巴坦作为头孢他啶-阿维巴坦、头孢地尔耐药的产KPC-3（KPC-3的D179Y变体）的ST-512的挽救治疗药物。
Open Forum Infect Dis. 2021 Mar 20;8(6):ofab141. doi: 10.1093/ofid/ofab141. eCollection 2021 Jun.
9
Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems.碳青霉烯类、氨基糖苷类、多黏菌素类和替加环素耐药的肺炎克雷伯菌、铜绿假单胞菌和鲍曼不动杆菌的治疗选择：基于碳青霉烯类耐药机制的方法。
Infection. 2020 Dec;48(6):835-851. doi: 10.1007/s15010-020-01520-6. Epub 2020 Sep 1.